Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

Abstract Background The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of erenumab treatment in a cohort of patients with difficult-to-control chroni...

Full description

Bibliographic Details
Main Authors: J. Talbot, R. Stuckey, L. Crawford, S. Weatherby, S. Mullin
Format: Article
Language:English
Published: BMC 2021-01-01
Series:The Journal of Headache and Pain
Subjects:
Chronic migraine
Erenumab
Aimovig
OnabotulinumtoxinA
Botox
CGRP antagonist
Online Access:https://doi.org/10.1186/s10194-020-01214-2

Similar Items

Similar Items